

IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE
– LODGEMENT OF OFFER INFORMATION STATEMENT AND INDICATIVE TIMETABLE OF
KEY EVENTS**

1. INTRODUCTION

The Board of Directors (the “**Board**” or “**Directors**”) of iX Biopharma Ltd. (the “**Company**”) refers to:

- (a) the Company’s announcements dated 6 June 2024, 11 June 2024 and 18 June 2024 in relation to the Rights cum Warrants Issue (the “**Earlier Announcements**”);
- (b) the Securities and Futures (Offers of Investments) (Temporary Exemption from Sections 277(1)(c) and 305B(1)(b)) Regulations 2020 (“**Temporary Exemption Regulations**”);
- (c) the guidelines on the Securities and Futures (Offers of Investments) (Temporary Exemption from Sections 277(1)(c) and 305B(1)(b)) Regulations 2020 (Guideline No.: SFA 13-G21) released by the Monetary Authority of Singapore on 6 May 2020 (“**Guidelines**”); and
- (d) the news release by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) on 29 June 2021 announcing that the Monetary Authority of Singapore, the Securities Industry Council and the Singapore Exchange Regulation have extended the option for listed issuers and parties involved in rights issues and take-over or merger transactions to electronically disseminate such offer documents through publication on SGX-ST and their corporate websites beyond 30 June 2021 until revoked or amended by the Monetary Authority of Singapore, the Securities Industry Council and the Singapore Exchange Regulation (together with the Temporary Exemption Regulations and the Guidelines, the “**Electronic Dissemination Measures**”).

Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Company’s offer information statement dated 26 June 2024 in relation to the Rights cum Warrants Issue (“**Offer Information Statement**”).

2. LODGEMENT, DESPATCH AND/OR DISSEMINATION OF THE OFFER INFORMATION STATEMENT AND ITS ACCOMPANYING DOCUMENTS

2.1 The Board wishes to announce that the Offer Information Statement has been lodged with the SGX-ST, acting as agent on behalf of the Monetary Authority of Singapore (“**Authority**”), on 26 June 2024.

2.2 Pursuant to the Electronic Dissemination Measures, printed copies of the Offer Information Statement will not be despatched to any person. The Offer Information Statement has instead been made available for viewing online in a Portable Document Format (PDF) at, and may be accessed, downloaded and printed from, the following online locations:

- (a) the corporate website of the Company at the following URL:

<https://www.ixbiopharma.com/newsroom/>

- (b) on the SGXNET announcement page at the following URL:

<https://www.sgx.com/securities/company-announcements?pagesize=100&value=IX%20BIOPHARMA%20LTD.&type=company>

(together, the “**Online Locations**”).

2.3 A printed copy of a notification letter specifying the Online Locations and containing, among others, instructions on how to access, view, download and print the electronic version of the Offer Information Statement (the “**Notification**”), together with the Application Form for Rights Shares with Warrants and Excess Rights Shares with Warrants (the “**ARE**”) or the Provisional Allotment Letter (the “**PAL**”), as the case may be, will be despatched to Entitled Shareholders on or around 1 July 2024.

2.4 For practical reasons and in order to avoid any violation of the securities legislation applicable in countries other than Singapore, the Offer Information Statement and its accompanying documents have not been and will not be despatched to Foreign Shareholders or into any jurisdiction outside Singapore. Accordingly, Foreign Shareholders will not be entitled to participate in the Rights cum Warrants Issue. No provisional allotment of the Rights Shares with Warrants has been made or will be made to Foreign Shareholders and no purported acceptance thereof or application therefor by any Foreign Shareholder will be valid.

3. REQUEST FOR THE NOTIFICATION AND THE ACCOMPANYING DOCUMENTS

3.1 Entitled Depositors who do not receive the ARE or ARS together with the Notification, may contact The Central Depository (Pte) Limited via its hotline at +65 6535 7511 or via email at asksgx@sgx.com, on Mondays to Fridays from 8.30 a.m. to 5.00 p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 15 July 2024 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

3.2 Entitled Scripholders who do not receive the PAL together with the Notification, may obtain a copy from the Share Registrar, Tricor Barbinder Share Registration Services at 9 Raffles Place, Republic Plaza, Tower 1, #26-01, Singapore 048619, on Mondays to Fridays from 9.00 a.m. to 5.00 p.m., during the period from the date the Rights cum Warrants Issue commences up to 5.30 p.m. on 15 July 2024 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

4. ACCEPTANCES OF PROVISIONAL ALLOTMENTS OF RIGHTS SHARES WITH WARRANTS AND (IF APPLICABLE) APPLICATION FOR EXCESS RIGHTS SHARES WITH WARRANTS

4.1 Acceptances of provisional allotments of Rights Shares with Warrants and (if applicable) applications for Excess Rights Shares with Warrants may only be made:

(a) in the case of Entitled Depositors:

(i) by way of the ARE through CDP, and/or

(ii) by way of an Electronic Application through an ATM of a Participating Bank or an Accepted Electronic Service; and

(b) in the case of Entitled Scripholders, by way of the PAL through the Share Registrar.

4.2 For SRS Investors and investors who hold Shares through finance companies or Depository Agents, acceptances of the Rights Shares with Warrants and (if applicable) applications for Excess Rights Shares with Warrants must be done through the relevant approved banks in which they hold their SRS accounts, and their respective finance companies or Depository Agents, as the case may be.

Such investors are advised to provide their respective approved banks in which they hold their SRS accounts, and their respective finance companies or Depository Agents, as the case may

be, with the appropriate instructions no later than the deadlines set by them in order for such intermediaries to make the relevant acceptances and (if applicable) applications on their behalf in accordance with the terms and conditions in the Offer Information Statement by the Closing Date.

Any acceptance and/or (if applicable) application by such investors made directly through CDP, Electronic Applications for Rights Shares with Warrants at any ATM of a Participating Bank or an Accepted Electronic Service, the Share Registrar and/or the Company will be rejected.

- 4.3 More information on the procedures for acceptance, payment and applications for Rights Shares with Warrants and Excess Rights Shares with Warrants by Entitled Shareholders can be found in the Offer Information Statement, the ARE and the PAL (as the case may be).

5. TRADING PERIOD OF NIL-PAID RIGHTS

- 5.1 The trading period for the provisional allotments of Rights Shares with Warrants (the "**Nil-Paid Rights**") on the SGX-ST will commence at 9.00 a.m. on 1 July 2024 and will end at 5.00 p.m. on 9 July 2024.

- 5.2 Entitled Depositors who sell their Nil-Paid Rights during this period need not forward the ARE to the Purchasers as arrangements will be made by CDP for a separate Application Form for Rights Shares with Warrants (being the "**ARS**") to be issued to the Purchasers. Purchasers should note that CDP will, for and on behalf of the Company, send the Notification and the ARS, **BY ORDINARY POST AND AT THE PURCHASERS' OWN RISK**, to their respective Singapore addresses as maintained in the records of CDP. For the avoidance of doubt, only Entitled Shareholders (and not the Purchasers or the renounees of Entitled Shareholders) shall be entitled to apply for additional Rights Shares with Warrants in excess of their provisional allotments of Rights Shares with Warrants.

- 5.3 For practical reasons and in order to avoid any violation of the securities legislation applicable in countries other than Singapore, the Offer Information Statement and its accompanying documents will not be despatched to Foreign Purchasers or into any jurisdiction outside Singapore. Foreign Purchasers who wish to accept the Rights Shares with Warrants credited to their Securities Accounts should make the necessary arrangements with their respective Depository Agents or stockbrokers in Singapore. The Company further reserves the right to reject any acceptances of the Rights Shares with Warrants and/or application for excess Rights Shares with Warrants where it believes, or has reason to believe, that such acceptance and/or application may violate the applicable legislation of any jurisdiction.

6. INDICATIVE TIMETABLE OF KEY EVENTS

Entitled Shareholders should take note of the following important dates and times in respect of the Rights cum Warrants Issue:

Last day Shares trade cum-rights	:	24 June 2024
Shares trade ex-rights	:	25 June 2024 from 9.00 a.m.
Record Date	:	26 June 2024 at 5.00 p.m.
Lodgement of Offer Information Statement and accompanying application forms with the SGX-ST, acting as agent on behalf of the Authority	:	26 June 2024
Despatch of the Notification (together with the ARE or PAL, as the case may be) to the Entitled Shareholders	:	1 July 2024
Commencement of trading of Nil-Paid Rights	:	1 July 2024 from 9.00 a.m.

Last date and time for splitting Rights Shares with Warrants	:	9 July 2024 at 5.30 p.m.
Last date and time for trading of Nil-Paid Rights	:	9 July 2024 at 5.00 p.m.
Last date and time for acceptance and payment of Rights Shares with Warrants	:	15 July 2024 at 5.30 p.m. (or 9.30 p.m. for Electronic Applications via ATM of Participating Banks)
Last date and time for acceptance of and payment for Rights Shares with Warrants by Renouncees ⁽¹⁾	:	15 July 2024 at 5.30 p.m. (or 9.30 p.m. for Electronic Applications via ATM of Participating Banks)
Last date and time for application and payment of Excess Rights Shares with Warrants	:	15 July 2024 at 5.30 p.m. (or 9.30 p.m. for Electronic Applications via ATM of Participating Banks)
Expected date for issuance of Rights Shares with Warrants	:	19 July 2024
Expected date for crediting of Rights Shares with Warrants	:	23 July 2024
Expected date for refund of unsuccessful applications (if made through CDP)	:	23 July 2024
Expected date for the commencement of trading of Rights Shares	:	23 July 2024
Expected date for the commencement of trading of Warrants	:	24 July 2024

Note:

(1) This does not apply to SRS Investors and investors who hold Shares through a finance company and/or a Depository Agent, where applicable. SRS Investors and investors who hold Shares through a finance company and/or Depository Agent should see the section entitled "Important Notice" of the Offer Information Statement. Such investors will receive notification letter(s) from their respective SRS Approved Banks, finance companies and/or Depository Agents and should refer to such notification letter(s) for details of the last date and time to submit applications to their respective SRS Approved Banks, finance companies and/or Depository Agents. Any acceptance of the Rights Shares with Warrants and (if applicable) application for Excess Rights Shares with Warrants made directly through CDP, Electronic Applications at any ATM of the Participating Bank or Accepted Electronic Service, the Share Registrar and/or the Company will be rejected.

The above timetable is indicative only and is subject to change. As at the date of this announcement, the Company does not expect the above timetable to be modified. However, the Company may, with the approval of the SGX-ST and/or CDP (if necessary), modify the above timetable subject to any limitations under any applicable laws. In such an event, the Company will publicly announce the same through an announcement released by the Company via SGXNET at <http://www.sgx.com>.

7. GENERAL

This announcement is qualified in its entirety by, and should be read in conjunction with, the full text of the Offer Information Statement. Where appropriate, further details will be disclosed in subsequent announcements.

IX BIOPHARMA LTD. BY ORDER OF THE BOARD

Eddy Lee Yip Hang
Chairman & CEO
26 June 2024

This announcement has been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited ("Sponsor").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.